Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response ...

Belrestotug (EOS-448/GSKFF28849A): IgG1 anti-TIGIT monoclonal antibody in development for the first-line treatment of locally advanced or metastatic PD-L1-high non-small cell lung cancer (NSCLC ...

Detailed price information for Iteos Therapeutics Inc (ITOS-Q) from The Globe and Mail including charting and trades.